Tag Archive for sales

Nature’s Sunshine Products Q2 Revenue Down 4.4% To $104.2 Million

Nature’s Sunshine Products, Inc. (Nasdaq: NATR) (Nature’s Sunshine), a leading natural health and wellness company of high-quality herbal and nutritional products, reported financial results for the second quarter ended June 30, 2022.
Second Quarter 2022 Financial Summary vs. Same Year-Ago Quarter
Net sales were $104.2 million compared to $109.0 million.
GAAP net income was $1.0 million, or $0.03 per diluted share, compared to $6.8 million, or $0.32 per diluted share.
Adjusted EBITDA was $9.0 million compared to $13.4 million.
Management Commentary
“The challenges facing our world certainly remained in the second quarter,”
said Terrence Moorehead, CEO of Nature’s Sunshine.
“The devastating war in Ukraine, rampant inflation, supply chain pressures, and the lingering impact of COVID-19 hampered our vision to share the healing power of nature with everyone.
Despite the headwinds, our revenue was flat on a constant currency basis, driven by continued rapid growth in Asia and mitigated losses in Europe. We believe these outcomes illuminate the resilience of our brand, the power of our vision, and the advantages of our global presence.
“As we look to the remainder of the year, we recognize the volatility and uncertainty of the operating environment.
However, we will continue to invest in our five global growth strategies and support our partners

Read more...

Mannatech Q2 Revenue Down 17,7% To $35 Million

Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2022.
Second Quarter End Results
Second quarter net sales for 2022 were $35.0 million, a decrease of $7.5 million, or 17.7%, as compared to $42.5 million in the second quarter of 2021.
Our net sales declined 11.3% on a constant dollar basis (see Non-GAAP Measures, below) as foreign exchange decreased GAAP net sales by $2.7 million, mostly due to the decline of the Korean Won and Japanese Yen.
During the second quarter, logistics in Hong Kong improved, and we were better able to deliver products to our customers. However, during the quarter, supply chain constraints worldwide continued to impact our sales. We have experienced a shortage of an ingredient used in some core products, and we have begun to move forward with our manufacturing partners with an alternative.
Second quarter operating income for 2022 was $0.9 million as compared to $2.0 million for the second quarter of 2021.
Net income was $0.7 million, or $0.34 per diluted share, for the second quarter of 2022, as compared to net income of $2.1 million, or $0.99 per diluted share,

Read more...

USANA Q2 Revenue Down 21% To $264 Million

USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal second quarter ended July 2, 2022.

Second quarter net sales were $264 million as compared with $337 million during the second quarter of the prior year.
Second quarter diluted EPS totaled $1.00 versus $1.87 during the second quarter of 2021.
Company reiterates fiscal 2022 net sales and diluted EPS outlook of $1.015 billion to $1.065 billion and $3.85 to $4.45, respectively.

“As indicated in our preliminary results release on July 6th, we continue to experience COVID-related disruptions in several key markets, including mainland China. This caused participation in sales programs, Active Customer counts, and financial performance to come in lower than anticipated,”
said Kevin Guest, Chief Executive Officer and Chairman of the Board.
“Although many of these disruptions were outside of our control, and while we faced a tough year-over year comparable due to the timing of a successful sales program in 2021, our second quarter results were not up to our standards.
Nevertheless, we remain committed to our business strategy which we believe will deliver sustained, long-term growth in customer counts, net sales, and EPS.
Important elements of this strategy include

enhancing digital experience for our customers to improve the overall online shopping experience;
improving

Read more...

Zeta Pays $1,4 Million In Commission In The First Month

According to a Zeta press release:
As Allan Badilla stated,
“The 4.0 revolution will make history”, Zeta Group, in its first month has achieved great results and in just 30 days has set multiple records in the industry.
This revolution came to be a benchmark for leadership and economic growth in Latin America and the world, through the leadership of Allan Badilla, Zeta has achieved that its most recognized leaders reach ranks that seemed impossible in such a short time.
The first of these achievements was achieved in just 7 days by Allan Badilla, who reached the double diamond rank, earning a commission of $70,000, demonstrating, once again, that, thanks to his leadership and constant work, it is possible to achieve high-level results in record time.
By reaching this rank, Allan made way for one of its strongest leaders to achieve in just two weeks, being the first Diamond Z, the entrepreneur Miguel Posada, reached this rank in record time.
Following the example of the double diamond, Miguel continues stating that his purpose is to positively impact people and show them that results like this are a reflection of the effort and dedication of a leading organization in a million-dollar industry.
June continued to be a

Read more...

USANA Q2 Preliminary Sales Down 21% To $265 Million

USANA Health Sciences, Inc. (NYSE: USNA) today announced preliminary results for the second quarter ended July 2, 2022, and provided an updated outlook for fiscal year 2022.
The Company anticipates that second quarter 2022 net sales will be approximately $265 million, which compares with $337 million in the prior-year period. Earnings per share for the quarter are expected to be approximately $1.05, which compares with $1.87 during the second quarter of 2021.
“Our sales performance during the second quarter was below expectations, as COVID-related lockdowns, restrictions, and other disruptions continued in mainland China and other markets,”
said Kevin Guest, Chief Executive Officer and Chairman of the Board.
“These challenges were particularly disruptive to the regional sales program we offered in several key markets during the quarter, and ultimately caused participation in the program, sales results and active customer counts to come in lower than anticipated.
Importantly, this program was designed to be a catalyst for sales and customer growth not only during the quarter, but also in the second half of the year. As a result of this and the continued uncertainty surrounding the operating environment going forward, we anticipate softer sales and customer counts in the second half of the year.”
“We continue to

Read more...

Stemtech Increases Recruitment By 38%

According to a Stemtech press release:
Stemtech Corporation (“Stemtech”) (CQB:OTSTEK), an innovative nutraceutical company and a pioneer in the field of stem cell nutrition, announced today that the Company increased independent business partner recruiting by 38% for the period from April 1, 2022 through June 20, 2022, as compared to the same period last year.
Independent business partners include distributors, customers, wholesale buyers, business builders and VIP Customers.
“We are thrilled about the recent increase in recruitment for Stemtech,”
said Charles Arnold, Chairman and CEO of Stemtech.
“Recruitment is the lifeblood of direct sales companies and we are very encouraged by our results so far in the second quarter of 2022. We intend to continue our outreach and expansion efforts, and build on this momentum going forward.”
Stemtech recently moved up 174 places in the Business For Home Momentum Ranks from the previous year, to achieve a ranking of 93 out of a total of 722 of the top companies in the industry. The results can be seen on the Business For Home web site at www.businessforhome.org.

Stemtech specializes in creating products and formulas that are patent protected in the U.S. and international markets. The Company’s patented formulas help the release, circulation and migration of

Read more...

Arieyl $16 Million In Sales With 50,000 Customers

According to an Arieyl press release:
When you look at their product names, the labeling, the opportunity videos, even the picture of the CEO’s on Business for Home – you know for a fact, that Arieyl is NOT your mama’s MLM.
Kristen and Travis Butler burst into the network marketing scene in November of 2020, this time stepping up as CEOs with passion, conviction, and a courageous promise to disrupt and elevate.
In true collaborative fashion, Arieyl’s founders and co-CEOs, Travis and Kristen Butler, teamed up with a small group of family, friends and proven industry leaders equipped with a diverse product line, a lucrative compensation plan and an unique opportunity for those with enough faith to join them on a “Rockstar” adventure.
Arieyl quickly exploded with over 1 million in sales their first week in business.
Opting to produce proprietary formulated supplements over white label stock items sets Arieyl apart from the majority of their competition and has even challenged other world class companies to elevate their existing lines.
Since Arieyl’s conception, only a year and a half ago, the debt free company boosts over 16 million in sales, 50,000 customers and more than 70 stellar health and wellness products.
It’s no wonder that 7,000

Read more...

Medifast – Optavia First Quarter Sales Up 22.6% To $417 Million

Medifast, Inc. (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, today reported results for the first quarter ended March 31, 2022.
First Quarter 2022 Highlights Compared to the Prior-Year Period

Revenue increased 22.6% to $417.6 million
21.7% growth in the number of active earning OPTAVIA Coaches to 63,900
Revenue per active earning OPTAVIA Coach increased 1.3% to $6,536
Net income increased 1.7% to $41.8 million
Earnings per diluted share (“EPS”) of $3.59, an increase of 3.8%
Annual revenue guidance raised to $1.78 billion to $1.84 billion and full-year EPS to $14.60 to $16.05

“Record quarterly revenues, sharp acceleration in coach metrics and an increase in our annual financial guidance are powerful indications of the underlying strength of our business.
We have record numbers of independent active earning OPTAVIA Coaches, helping us drive robust product demand and rapidly increasing digital engagement, and bolstering OPTAVIA to the #1 revenue share position among publicly traded companies in the weight management industry in the United States,”
said Dan Chard, Chairman and Chief Executive Officer of Medifast.
“We continue to take advantage of significant opportunities to further leverage our technological innovation and infrastructure. Through deeper integration of key technologies and data analytics, we are enhancing the OPTAVIA customer experience and enabling significant productivity gains for OPTAVIA Coaches.
All of this creates strong potential for further expansion into the broader

Read more...